A potential role of preexisting inflammation in the development of acute myelopathy following CAR T-cell therapy for diffuse large B-cell lymphoma
- 1 May 2022
- journal article
- research article
- Published by Elsevier BV in Current Research in Translational Medicine
- Vol. 70 (2), 103331
- https://doi.org/10.1016/j.retram.2021.103331
Abstract
No abstract availableKeywords
Funding Information
- ARC Foundation for Cancer Research
This publication has 19 references indexed in Scilit:
- Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell LymphomaThe New England Journal of Medicine, 2019
- CAR T cell–induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockadeNature Medicine, 2018
- Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cellsNature Medicine, 2018
- T helper 17.1 cells associate with multiple sclerosis disease activity: perspectives for early interventionBrain, 2018
- Insights into cytokine release syndrome and neurotoxicity after CD19-specific CAR-T cell therapyCurrent Research in Translational Medicine, 2018
- Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell LymphomaThe New England Journal of Medicine, 2017
- Endothelial Activation and Blood–Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T CellsCancer Discovery, 2017
- Chimeric antigen receptor T-cell therapy — assessment and management of toxicitiesNature Reviews Clinical Oncology, 2017
- IVIG Treatment and Prognosis in Guillain–Barré SyndromeJournal of Clinical Immunology, 2010
- IL-6 induces regionally selective spinal cord injury in patients with the neuroinflammatory disorder transverse myelitisJCI Insight, 2005